- Home
- VERI vs INKT Comparison
VERI vs INKT Comparison
Compare VERI & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VERI | INKT |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.7M | 59.4M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VERI | INKT |
|---|---|---|
| Price | $0.64 | $10.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.50 | ★ $42.50 |
| AVG Volume (30 Days) | ★ 6.2M | 14.3K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $92,637,000.00 | N/A |
| Revenue This Year | $11.05 | N/A |
| Revenue Next Year | $33.37 | $44.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $8.48 |
| 52 Week High | $6.91 | $15.27 |
Technical Indicators
Market Signals| Indicator | VERI | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 42.73 | 45.59 |
| Support Level | $0.51 | $9.05 |
| Resistance Level | $1.56 | $12.27 |
| Average True Range (ATR) | 0.05 | 0.69 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 79.42 | 51.74 |
Price Performance
Historical ComparisonAbout VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has presence in the United States, the United Kingdom, France, Australia, Israel, and India.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.